BiotechTube
AATec Medical

AATec Medical

Munich, Germany· Est.
aatec-medical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AATec Medical, founded in 2016 and based in Munich, is a preclinical-stage biotech targeting major unmet needs in inflammatory respiratory diseases. Its core asset is a proprietary recombinant Alpha-1 Antitrypsin (AAT) platform, designed with multimodal anti-protease, immunomodulatory, and anti-infective properties for direct lung delivery. The lead candidate, ATL-105, is being developed for non-cystic fibrosis bronchiectasis (NCFB), with clinical studies planned for 2026, and has potential expansion into large markets like COPD and asthma.

Respiratory DiseasesInflammatory Diseases

Technology Platform

Proprietary recombinant Alpha-1 Antitrypsin (AAT) platform with multimodal (anti-protease, immunomodulatory, anti-infective) properties, combined with a dedicated handheld protein nebulization technology for targeted lung delivery.

Opportunities

The lead indication (NCFB) represents a high-unmet-need market with peak sales potential of $1.8 billion.
The platform has clear expansion potential into massive respiratory markets like COPD and asthma, targeting neutrophilic inflammation, and into acute conditions like ARDS.
The targeted lung delivery system offers a potential best-in-class safety and efficacy profile.

Risk Factors

The company is at a preclinical stage, facing high biological and clinical development risk.
It will face competition in both its lead and expansion indications from larger, well-resourced players.
Future success is dependent on securing additional significant capital to fund clinical development through to later stages.

Competitive Landscape

In NCFB, the competitive landscape is emerging but not yet crowded, with limited approved therapies. In broader markets like COPD and asthma, AATec would compete against large pharmaceutical companies with extensive portfolios of biologics and small molecules, requiring clear differentiation on mechanism (targeting neutrophilic inflammation) and route of administration (inhaled biologic).

More companies in Biologics / Biosimilars →More companies in Germany →